Neurocrine Biosciences names returning CMO, parts ways with Keswani

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced that Eiry W. Roberts, M.D., will rejoin the company as Chief Medical Officer, effective immediately, according to a press release dated Sept. 28, 2026.

Dr. Roberts previously held the CMO role at Neurocrine from 2018 to 2025 and has since served as a Strategic Advisor to the company. By mutual agreement, incumbent CMO Sanjay Keswani, M.D., will depart.

During her prior tenure as CMO, Dr. Roberts led indication-expansion efforts for INGREZZA and the crinecerfont development program that resulted in FDA approval of CRENESSITY. Before joining Neurocrine in 2018, she spent 26 years at Eli Lilly and Company, where she held senior research and development roles including Vice President, Research and Development. She currently serves on the Board of Directors of Bausch Health Companies.

"Her deep knowledge of Neurocrine, our pipeline and our clinical development programs provides strong continuity at a time when we are advancing multiple late-stage programs and preparing for several important clinical milestones," said Kyle W. Gano, Ph.D., President and Chief Executive Officer of Neurocrine Biosciences.

"I am honored to assume the Chief Medical Officer role again and contribute to our mission of relieving suffering for people with unmet needs," Dr. Roberts said.

You May Also Be Interested In

• TG Therapeutics reports Phase 1 azer-cel data in progressive MS
• Niki BioSolutions unit signs APOE genotyping deal with Charter Research
• Tango reports 82% response rate in pancreatic cancer drug study